IKNA Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs...

Stats
Dzisiejszy wolumen	367 590
Średni wolumen	392 743
Kapitalizacja rynkowa	63.70M
EPS	$0 ( 2024-03-12 )
Następna data zysków	( $-0.400 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.810
ATR14	$0.00600 (0.46%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Germa Caroline	Buy	579 100	Stock Option (Right to Buy)
2024-02-29	Germa Caroline	Buy	0
2024-02-01	Ecsedy Jeffrey	Buy	100 000	Stock Option (Right to Buy)
2024-02-01	Marango Jotin	Buy	181 000	Stock Option (Right to Buy)
2024-02-01	Manfredi Mark	Buy	320 000	Stock Option (Right to Buy)

INSIDER POWER
96.17
Last 94 transactions
Buy: 20 809 745 \| Sell: 873 348

Wolumen Korelacja

Długi: -0.14 (neutral)

Krótki: -0.79 (moderate negative)

Signal:(44.496) Neutral

Ikena Oncology, Inc. Korelacja

10 Najbardziej pozytywne korelacje
RMRM	0.946
AEHR	0.928
VRAY	0.925
XPDI	0.921
TCDA	0.92
FDBC	0.919
AXDX	0.919
APOP	0.919
RNAZ	0.915
EVOK	0.912

10 Najbardziej negatywne korelacje
TAST	-0.941
BOCH	-0.939
SUMO	-0.936
MRTX	-0.932
FFNW	-0.925
DSPG	-0.918
STAY	-0.917
MMAC	-0.917
DSEY	-0.914
SFBC	-0.912

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ikena Oncology, Inc. Korelacja - Waluta/Towar

0.06
( neutral )

-0.13
( neutral )

0.00
( neutral )

0.04
( neutral )

Ikena Oncology, Inc. Finanse

Annual	2023
Przychody:	$9.16M
Zysk brutto:	$8.14M (88.86 %)
EPS:	$-1.630

FY	2023
Przychody:	$9.16M
Zysk brutto:	$8.14M (88.86 %)
EPS:	$-1.630

FY	2022
Przychody:	$15.62M
Zysk brutto:	$13.58M (86.98 %)
EPS:	$-1.840

FY	2021
Przychody:	$30.99M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.951

Financial Reports:

No articles found.

Ikena Oncology, Inc.

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.